TY - JOUR
T1 - Risk profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan ― Insights from GARFIELD-AF ―
AU - GARFIELD-AF Investigators
AU - Koretsune, Yukihiro
AU - Etoh, Takuma
AU - Katsuda, Yousuke
AU - Suetsugu, Tetsuro
AU - Kumeda, Kenshi
AU - Sakuma, Ichiro
AU - Eshima, Kenichi
AU - Shibuya, Mitsuhiro
AU - Ando, Shin Ichi
AU - Yokota, Naoto
AU - Goto, Shinya
AU - Pieper, Karen S.
AU - Allu, Jagan
AU - Kakkar, Ajay K.
N1 - Funding Information:
This work was supported by an unrestricted research grant from Bayer AG (Berlin, Germany) to the Thrombosis Research Institute (London, UK), which sponsors the GARFIELD-AF registry. The funding source had no involvement in the data collection, data analysis, or data interpretation.
Funding Information:
Y. Koretsune, research grant: Daiichi Sankyo and Boehringer Ingelheim; paid lecture: Daiichi Sankyo, Boehringer Ingelheim, Bayer, Bristol Meyers and Pfizer. I.S., paid lecture: Bayer, and Takeda. K.S.P., consultant for Thrombosis Research Institute, AstraZeneca, and Bayer. S.G., research grant from Bristol Meyers, Pfizer, Ono, and Sanofi; honoraria for speaking or participation at meetings from Bayer, and AstraZeneca. A.K.K., grants from Bayer AG, during the conduct of the study; grants and personal fees from Bayer AG, personal fees from Boehringer-Ingelheim Pharma, personal fees from Daiichi Sankyo Europe, personal fees from Janssen Pharma, personal fees from Sanofi SA, outside the submitted work. The other authors declare no conflicts of interest.
Publisher Copyright:
© 2019, Japanese Circulation Society. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Background: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective non-inter-ventional study of stroke prevention in patients with newly diagnosed non-valvular AF (NAVF) that is being conducted in 35 countries. Methods and Results: A total of 52,081 patients with a new diagnosis of NVAF were enrolled prospectively in GARFIELD-AF. Of these, 4859 (9.3%) were recruited in Japan (2010–2016). In cohort 1 (2010–2011), few patients were on non-vitamin K antagonist oral anticoagulants (NOAC) globally. From cohort 2 onwards (2011–2016), however, there was a rapid increase in NOAC use around the globe, especially in Japan. By the last year of enrolment (2015–2016), 67.9% of patients in Japan and 43.1% of patients globally were on NOAC ± antiplatelet therapy (AP). In Japan and globally, 17.0% and 12.2% of patients, respectively, did not receive stroke prevention treatment. Few patients in Japan (5.7%) received AP only. Compared with the other countries, the unadjusted rates of all-cause mortality and major bleeding were low, while rates of stroke/systemic embolism were similar after 1 year of follow-up. Conclusions: GARFIELD-AF continues to provide important information on the homogeneity and heterogeneity of baseline characteristics and treatment patterns in patients with newly diagnosed NVAF. This diversity reflects the differences in outcomes in Japan compared with the rest of the world.
AB - Background: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective non-inter-ventional study of stroke prevention in patients with newly diagnosed non-valvular AF (NAVF) that is being conducted in 35 countries. Methods and Results: A total of 52,081 patients with a new diagnosis of NVAF were enrolled prospectively in GARFIELD-AF. Of these, 4859 (9.3%) were recruited in Japan (2010–2016). In cohort 1 (2010–2011), few patients were on non-vitamin K antagonist oral anticoagulants (NOAC) globally. From cohort 2 onwards (2011–2016), however, there was a rapid increase in NOAC use around the globe, especially in Japan. By the last year of enrolment (2015–2016), 67.9% of patients in Japan and 43.1% of patients globally were on NOAC ± antiplatelet therapy (AP). In Japan and globally, 17.0% and 12.2% of patients, respectively, did not receive stroke prevention treatment. Few patients in Japan (5.7%) received AP only. Compared with the other countries, the unadjusted rates of all-cause mortality and major bleeding were low, while rates of stroke/systemic embolism were similar after 1 year of follow-up. Conclusions: GARFIELD-AF continues to provide important information on the homogeneity and heterogeneity of baseline characteristics and treatment patterns in patients with newly diagnosed NVAF. This diversity reflects the differences in outcomes in Japan compared with the rest of the world.
UR - http://www.scopus.com/inward/record.url?scp=85059072165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059072165&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-18-0655
DO - 10.1253/circj.CJ-18-0655
M3 - Article
C2 - 30518731
AN - SCOPUS:85059072165
SN - 1346-9843
VL - 83
SP - 67
EP - 74
JO - Circulation Journal
JF - Circulation Journal
IS - 1
ER -